FDA Brief

Warning letters Drugs

FDA warning letter to

Linghai ZhanWang Biotechnology Co., Ltd

High riskIssued Feb 25, 2025Posted Mar 11, 2025Center for Drug Evaluation and Research (CDER)

Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.

What happened

FDA reviewed records and other information the company submitted after FDA's February 26, 2024 request under section 704(a)(4) of the FD&C Act, plus later correspondence. FDA found significant Current Good Manufacturing Practice (CGMP) violations for finished drugs: the company did not test components such as ethanol for methanol or glycerin and (b)(4) for DEG/EG, lacked an adequate stability program for its anti-microbial wipes, and its quality unit did not effectively oversee quality. FDA placed all drugs and drug products offered for import into the United States from the firm on Import Alert 66-40 on February 10, 2025.

What FDA found

  1. The firm did not test each component for identity and conformity with written specifications for purity, strength, and quality; for example, it did not test ethanol for methanol or glycerin and (b)(4) for diethylene glycol and ethylene glycol.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  2. The firm lacked an adequate stability program; it used unjustified accelerated aging and did not perform long-term studies to support the labeled expiration date.

    21 CFR 211.166(a)
  3. The firm's quality unit did not effectively exercise its responsibility and authority to approve or reject components, packaging materials, labeling, and drug products.

    21 CFR 211.22(a)

What FDA wants

Respond in writing within 15 working days with what the company has done to correct the violations and prevent recurrence; if corrective actions cannot be completed in that time, state why and give a completion schedule. FDA may withhold approval of new applications or supplements listing the firm and may continue to refuse imports until compliance is confirmed.

Who should pay attention

  • brands that buy OTC drugs or antimicrobial wipes from this manufacturer
  • US importers and distributors of its drug products
  • companies sourcing ethanol- or glycerin-based OTC products from China

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk